Details for New Drug Application (NDA): 022012
✉ Email this page to a colleague
The generic ingredient in COREG CR is carvedilol phosphate. There is one drug master file entry for this compound. Nine suppliers are listed for this compound. Additional details are available on the carvedilol phosphate profile page.
Summary for 022012
| Tradename: | COREG CR |
| Applicant: | Waylis Therap |
| Ingredient: | carvedilol phosphate |
| Patents: | 1 |
Pharmacology for NDA: 022012
| Mechanism of Action | Adrenergic alpha-Antagonists Adrenergic beta1-Antagonists Adrenergic beta2-Antagonists |
Suppliers and Packaging for NDA: 022012
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| COREG CR | carvedilol phosphate | CAPSULE, EXTENDED RELEASE;ORAL | 022012 | NDA | Waylis Therapeutics LLC | 80725-383 | 80725-383-13 | 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (80725-383-13) |
| COREG CR | carvedilol phosphate | CAPSULE, EXTENDED RELEASE;ORAL | 022012 | NDA | Waylis Therapeutics LLC | 80725-385 | 80725-385-13 | 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (80725-385-13) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE, EXTENDED RELEASE;ORAL | Strength | 10MG | ||||
| Approval Date: | Oct 20, 2006 | TE: | AB | RLD: | Yes | ||||
| Patent: | ⤷ Start Trial | Patent Expiration: | Mar 11, 2026 | Product Flag? | Substance Flag? | Delist Request? | Y | ||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE, EXTENDED RELEASE;ORAL | Strength | 20MG | ||||
| Approval Date: | Oct 20, 2006 | TE: | AB | RLD: | Yes | ||||
| Patent: | ⤷ Start Trial | Patent Expiration: | Mar 11, 2026 | Product Flag? | Substance Flag? | Delist Request? | Y | ||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE, EXTENDED RELEASE;ORAL | Strength | 40MG | ||||
| Approval Date: | Oct 20, 2006 | TE: | AB | RLD: | Yes | ||||
| Patent: | ⤷ Start Trial | Patent Expiration: | Mar 11, 2026 | Product Flag? | Substance Flag? | Delist Request? | Y | ||
Complete Access Available with Subscription
